Yaritza Rodriguez Ogando
Adult Health · Orlando, FLNPI 1720703192
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,422 and has fallen 98.1% since, to $27 in 2024.
Across 77 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$283
- Pfizer$256
- Novo Nordisk$247
- Lilly USA, LLC$232
- AstraZeneca$170
- Exact Sciences$97
- plus $220 from 7 others
What the payments were for
- Food & beverage$1,504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $283 |
| Pfizer | 14 | $256 |
| Novo Nordisk | 14 | $247 |
| Lilly USA, LLC | 13 | $232 |
| AstraZeneca | 9 | $170 |
| Exact Sciences | 5 | $97 |
| Abbott | 3 | $64 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Amgen | 2 | $32 |
| Vivus LLC | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$1,504 in reported general payments places this provider in the 70th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 15 | $360 |
| Mupirocin | 25 | $158 |
| Pantoprazole Sodium | 18 | $130 |
| Levothyroxine Sodium | 14 | $124 |
| Lisinopril | 12 | $119 |
| Ondansetron OdtOndansetron | 17 | $110 |
| Losartan Potassium | 16 | $101 |
| Methocarbamol | 16 | $90 |
| Atorvastatin Calcium | 12 | $77 |
Paid to pharmacies, not to this prescriber.
Other adult health in Orlando
- Sita SwamyOrlando$49K
- Andreina NeallOrlando$16K
- Jessica SettineriOrlando$14K
- Kristen KessingerOrlando$13K
- Angelo LewisOrlando$12K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.